MediWound Ltd. (MDWD), a biopharmaceutical company, Tuesday said that data from the post hoc analysis of Phase 2 ChronEx study of EscharEx in patients with venous leg ulcers has been published in the peer-reviewed journal Wounds.
The analysis, based on the Phase II ChronEx study evaluating EscharEx compared with collagenase ointment, SANTYL showed that complete debridement was achieved in 63% of EscharEx-treated patients, at 2 weeks, compared to 0% in the SANTYL group.
Wound Bed Preparation or complete debridement and complete granulation was achieved by 50% of patients treated with EscharEx in 2 weeks vs. 0% with SANTYL, and Wound Closure was achieved in 33% of EscharEx patients vs. 25% with SANTYL.
"Compared to SANTYL, EscharEx achieved faster and more effective debridement and promoted healthier granulation tissue, both key to optimal wound bed preparation. EscharExs enzymatic formulation targets a wider range of non-viable and necrotic tissue, which may account for the favorable clinical outcomes observed," said Cyaandi Dove, DPM, of the University of Texas Health Science Center at San Antonio and co-author of the publication.
For comments and feedback: editorial@rttnews.com